Lovenox Patent Invalidity Ruling Could Open Door To Near-Term Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
California court invalidates Sanofi-Aventis’ patent due to inequitable conduct. The court’s ruling will lead to lifting of 30-month stay on ANDA approvals. Amphastar and Teva said they would await FDA approval of their enoxaparin generics before deciding whether to launch prior to an appellate court ruling.